Search results for ''
FEDERG meeting – Federation of European Patient Groups affected by Rare/Genetic Kidney Diseases
14 September 2024
Martorell, Spain
The Federation of European Patient Groups affected by Rare/Genetic Kidney Diseases, FEDERG, was organising its “fighting for our federation Federg f2f Members” meeting on the 14th of September in Martorell in Spain. The objective of the meeting was to plan new practical actions that help improve and promote knowledge of these pathologies, promote research, and be an active part in the political decision-making process for the inclusion of our pathologies.
The first patient dosed in the Phase 2 ALPESTRIA-1 clinical study of Vonafexor for Alport syndrome
The first patient with Alport Syndrome received their first oral doses of Vonafexor last month in the US as part of our Phase 2 ALPESTRIA-1 clinical study.
ALPESTRIA-1 evaluates the safety and the effects of Vonafexor on kidney function in subjects with at risk of progression Alport syndrome. The total duration of study for a participant will be up to 40 weeks and include a screening period, a treatment period of 24 weeks and a follow-up period of 12 weeks.
The Phase 2 ALPESTRIA-1 clinical study has started with Vonafexor on Alport syndrome
The ALPESTRIA-1 Phase 2 clinical study (NCT06425055) is an open-label, single arm, fixed dose escalation of the investigational drug Vonafexor. This study is a proof-of-concept trial of Vonafexor safety, its effects on kidney function in subjects with at risk of progression Alport syndrome. The study aims to recruit 20 patients in the US and EU (France, Spain and Germany).
The first site for patient recruitment is now open in Idaho (US) and more sites will open in the coming weeks.
Alport syndrome
At ENYO Pharma, patients with impaired kidney function are in the center of our discussions.
We are committed every day to develop new therapeutics for improving the quality of life of patients with Alport syndrome. Working closely with our patient advocacy partners, as key players as representatives of patients, families and caregivers, support our best strategy for clinical study development in Alport syndrome.
ALPESTRIA-1 clinical trial
We are aiming to preserve kidney function and reverse kidney damage with the investigational drug Vonafexor tested in our Phase 2 clinical study named “ALPESTRIA-1”.
ASN Kidney Week 2024
23-27 October 2024
San Diego, CA
ENYO Pharma will attend the world’s premier nephrology meeting of the American Society of Nephrology, ASN Kidney Week.
https://www.asn-online.org/education/kidneyweek/2024/important-dates.aspx
Latest Press Release 